PAR

Par Drugs & Chemicals Share Price

 

 

Start SIP in PAR

Start SIP

Performance

  • Low
  • ₹92
  • High
  • ₹96
  • 52 Week Low
  • ₹81
  • 52 Week High
  • ₹206
  • Open Price₹96
  • Previous Close₹93
  • Volume5,552
  • 50 DMA₹98.44
  • 100 DMA₹100.60
  • 200 DMA₹113.32

Investment Returns

  • Over 1 Month + 0.72%
  • Over 3 Month -9.23%
  • Over 6 Month -1.68%
  • Over 1 Year -49.26%

Smart Investing Starts Here Start SIP with Par Drugs & Chemicals for Steady Growth!

Invest Now

Par Drugs & Chemicals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 11.8
  • PEG Ratio
  • -0.3
  • Market Cap Cr
  • 114
  • P/B Ratio
  • 1.1
  • Average True Range
  • 5.05
  • EPS
  • 7.87
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.12
  • RSI
  • 38.92
  • MFI
  • 15.58

Par Drugs & Chemicals Financials

Par Drugs & Chemicals Technicals

EMA & SMA

Current Price
₹92.71
-0.62 (-0.66%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹97.80
  • 50 Day
  • ₹98.44
  • 100 Day
  • ₹100.60
  • 200 Day
  • ₹113.32

Resistance and Support

93.59 Pivot Speed
  • R3 98.60
  • R2 97.22
  • R1 94.97
  • S1 91.34
  • S2 89.96
  • S3 87.71

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Par Drugs and Chemicals has an operating revenue of Rs. 98.42 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 18% is great, ROE of 13% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 23% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 37 which is a POOR score indicating inconsistency in earnings, a RS Rating of 39 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Par Drugs & Chemicals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-08-29 Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-08-07 Quarterly Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-05-08 Audited Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-02-14 Quarterly Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
Date Purpose Remarks
2021-04-28 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 10/-.

Par Drugs & Chemicals F&O

Par Drugs & Chemicals Shareholding Pattern

73.37%
0%
20.27%
6.36%

About Par Drugs & Chemicals

  • NSE Symbol
  • PAR
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Falgun Vallabhbhai Savani
  • ISIN
  • INE04LG01015

Similar Stocks to Par Drugs & Chemicals

Par Drugs & Chemicals FAQs

Par Drugs & Chemicals share price is ₹92 As on 14 January, 2026 | 22:29

The Market Cap of Par Drugs & Chemicals is ₹114.1 Cr As on 14 January, 2026 | 22:29

The P/E ratio of Par Drugs & Chemicals is 11.8 As on 14 January, 2026 | 22:29

The PB ratio of Par Drugs & Chemicals is 1.1 As on 14 January, 2026 | 22:29

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23